Posted by Michael Wonder on 28 May 2022
Amneal achieves third U.S. biosimilar approval with Fylnetra (pegfilgrastim-pbbk)
27 May 2022 - Marks Amneal’s third biosimilar approval in 2022.
Amneal Pharmaceuticals today announced that the U.S. FDA has approved the Company’s biologics license application for pegfilgrastim-pbbk, a biosimilar referencing Neulasta.
The product will be marketed under the proprietary name Fylnetra.
